Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients
Article first published online: 9 OCT 2008
Volume 54, Issue 10, pages 1110–1113, October 1999
How to Cite
Di Rienzo, V., Pagani, A., Parmiani, S., Passalacqua, G. and Canonica, G.W. (1999), Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy, 54: 1110–1113. doi: 10.1034/j.1398-9995.1999.00267.x
- Issue published online: 9 OCT 2008
- Article first published online: 9 OCT 2008
- Accepted for publication 27 May 1999
- 1Immunotherapy as preventive treatment. J Allergy Clin Immunol 1996;97:232, , , et al.
- 3WHO Position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Bousquet J, Lockey RF, Malling H-J, editors. Allergy 1998;53 Suppl 44
- 6Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23:173 178, , , .
- 13Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996;21:146 151, , , et al.
- 15Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662 672, , , et al.
- 18New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Arbeiten aus dem Paul Ehrlich Institut. Stuttgart: Gustav Fischer Verlag, 1994, , .